Details der Publikation - A study to evaluate the effects of GLPG2737 in subjects with autosomal dominant polycystic kidney disease

A study to evaluate the effects of GLPG2737 in subjects with autosomal dominant polycystic kidney disease : An exploratory, randomized, double-blind, placebo-controlled, multicenterstudy to evaluate the efficacy, safety, tolerability and pharmacokinetics oforally administered GLPG2737 for 52 weeks, followed by an open-labelextension period of 52 weeks in subjects with autosomal dominantpolycystic kidney disease

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 01. Feb. Zur Gesamtaufnahme - year:2022

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Autosomal dominant polycystic kidney disease MedDRA version: 20.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-07-2020, Last updated: 2022-11-24

ICTRP ID:	EUCTR2019-003521-21-CZ GLPG2737-CL-203 2019-003521-21-BE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO004403789

Internformat


LEADER	01000caa a22002652 4500
001	WHO004403789
003	DE-627
005	20230425172009.0
007	cr uuu---uuuuu
008	210507s2022 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO004403789
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2019-003521-21-CZ
035			\|a (UBBS_Klinische_Studien_WHO)GLPG2737-CL-203
035			\|a (UBBS_Klinische_Studien_WHO)2019-003521-21-BE
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A study to evaluate the effects of GLPG2737 in subjects with autosomal dominant polycystic kidney disease \|b An exploratory, randomized, double-blind, placebo-controlled, multicenterstudy to evaluate the efficacy, safety, tolerability and pharmacokinetics oforally administered GLPG2737 for 52 weeks, followed by an open-labelextension period of 52 weeks in subjects with autosomal dominantpolycystic kidney disease
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 28-07-2020, Last updated: 2022-11-24
650		4	\|a Medical Condition: Autosomal dominant polycystic kidney disease MedDRA version: 20.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 01. Feb.
773	1	8	\|g year:2022 \|g day:01 \|g month:02
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003521-21 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 01 \|c 02

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände